UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Major and Minor Classifications for Surgery in People With Hemophilia: A Literature Review

Clinical and Applied Thrombosis/Hemostasis, 2018-05, Vol.24 (4), p.549-559

2018

Volltextzugriff (PDF)

Safety update on the use of recombinant activated factor VII in approved indications

Blood reviews, 2015-06, Vol.29, p.S34-S41

2015

Volltextzugriff (PDF)

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

BMJ open diabetes research & care, 2023-06, Vol.11 (3), p.e003300

2023

Volltextzugriff (PDF)

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Blood, 2020-11, Vol.136 (Supplement 1), p.40-40

2020

Volltextzugriff (PDF)

Mim8 Clinical Development Program: An Overview of the Frontier Studies

Blood, 2022-11, Vol.140 (Supplement 1), p.5630-5631

2022

Volltextzugriff (PDF)

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s5), p.1-2

SEREMETIS, STEPHANIE

2012

Volltextzugriff (PDF)

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s5), p.1-2

SEREMETIS, STEPHANIE

2012

Volltextzugriff (PDF)

11th Novo Nordisk Symposium on Haemostasis Management Vienna, Austria. 19-21 October 2011. Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 Suppl 5, p.1-2

Seremetis, Stephanie

2012

Volltextzugriff (PDF)

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18, p.1-2

SEREMETIS, STEPHANIE

2012

Volltextzugriff (PDF)

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Journal of thrombosis and haemostasis, 2019-09, Vol.17 (9), p.1470-1477

2019

Volltextzugriff (PDF)

Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion

Thrombosis and haemostasis, 2003-05, Vol.89 (5), p.803-811

2003

Volltextzugriff (PDF)

The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia

Thrombosis and haemostasis, 2002-10, Vol.88 (4), p.545-553

2002

Volltextzugriff (PDF)

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Blood, 2017-12, Vol.130, p.2372-2372

2017

Volltextzugriff (PDF)

The use of recombinant activated factor VII in patients with acquired haemophilia

Blood reviews, 2015-06, Vol.29, p.S19-S25

2015

Volltextzugriff (PDF)

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Blood coagulation & fibrinolysis, 2003-06, Vol.14 Suppl 1 (SUPPLEMENT 1), p.S29-S30

Seremetis, Stephanie

2003

Volltextzugriff (PDF)

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Clinical investigation, 2015-09, Vol.5 (9), p.755-766

2015

Volltextzugriff (PDF)

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-09, Vol.15 (5), p.1074-1082

2009

Volltextzugriff (PDF)

Turoctocog alfa and drug development for hemophilia A

Expert opinion on orphan drugs, 2014-04, Vol.2 (4), p.419-431

2014

Volltextzugriff (PDF)

Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review

Blood coagulation & fibrinolysis, 2009-10, Vol.20 (7), p.488-493

2009

Volltextzugriff (PDF)

Recombinant activated Factor VII in major surgery and trauma patients: a response

Expert opinion on drug safety, 2005-09, Vol.4 (5), p.813-814

2005

Volltextzugriff (PDF)

Recombinant activated Factor VII in major surgery and trauma patients: a response: Wilson SJ, Bellamy MC, Giannoudis PV: The safety and efficacy of the administration of recombinant activated Factor VII in major surgery and trauma patients. Expert Opin. Drug Saf. (2005) 4(3):557-570

Expert opinion on drug safety, 2005-09, Vol.4 (5), p.813-814

2005

Volltextzugriff (PDF)

Evidence-based use of recombinant FVIIa (NovoSeven® , NiaStase® ) for the treatment of hemophilia with inhibitors in children and adolescents

Transfusion and apheresis science, 2008-02, Vol.38 (1), p.25-32

2008

Volltextzugriff (PDF)

Safety of Recombinant Activated Coagulation Factor VII in Non-Hemophilia Patients

Blood, 2004-11, Vol.104 (11), p.3978-3978

2004

Volltextzugriff (PDF)

Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers

Blood, 2005-11, Vol.106 (11), p.4053-4053

2005

Volltextzugriff (PDF)

Variations in Ex-Vivo Assessments of Hemostasis

Blood, 2005-11, Vol.106 (11), p.4052-4052

2005

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(42)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Major and Minor Classifications for Surgery in People With Hemophilia: A Literature Review

Safety update on the use of recombinant activated factor VII in approved indications

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Mim8 Clinical Development Program: An Overview of the Frontier Studies

Introduction

Introduction

11th Novo Nordisk Symposium on Haemostasis Management Vienna, Austria. 19-21 October 2011. Introduction

Introduction

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion

The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

The use of recombinant activated factor VII in patients with acquired haemophilia

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

Turoctocog alfa and drug development for hemophilia A

Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review

Recombinant activated Factor VII in major surgery and trauma patients: a response

Recombinant activated Factor VII in major surgery and trauma patients: a response: Wilson SJ, Bellamy MC, Giannoudis PV: The safety and efficacy of the administration of recombinant activated Factor VII in major surgery and trauma patients. Expert Opin. Drug Saf. (2005) 4(3):557-570

Evidence-based use of recombinant FVIIa (NovoSeven® , NiaStase® ) for the treatment of hemophilia with inhibitors in children and adolescents

Safety of Recombinant Activated Coagulation Factor VII in Non-Hemophilia Patients

Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers

Variations in Ex-Vivo Assessments of Hemostasis

Aktive Filter

Suchergebnisse filtern